Most children diagnosed with acute lymphoblastic leukemia (ALL) will achieve remission and be cured of their disease. However, this high cure rate comes at the cost of acute and chronic treatment-related toxicities. In fact, a similar number of children die from either ALL itself or the toxicities associated with its treatment. Therapy-related toxicities, whether acute or chronic, can impact treatment efficacy, overall survival (OS), and the patient's quality of life. This review focused on six major acute toxicities of ALL therapy, venous thromboembolism, osteonecrosis, neurological sequels, delayed MTX elimination, asparaginase-associated pancreatitis, and toxicities of the new biological therapies. Most of these severe acute toxicities of ALL treatment can be mitigated through tailored therapy adaptations for individual patients and careful incorporation of immunotherapy. These adaptations will soon become a central component of contemporary pediatric ALL protocols and ultimately improve patients' OS and Wellness.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3324/haematol.2024.285702 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart.
Eur J Heart Fail
March 2025
Berlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the implementation of effective treatments. Therefore, there is a crucial need for appropriate preclinical models to understand the biological basis of their cardiotoxicity.
View Article and Find Full Text PDFApplication of Artificial Intelligence in Cardio-Oncology Imaging for Cancer Therapy-Related Cardiovascular Toxicity: A Systematic Review.
JMIR Cancer
March 2025
College of Public Health, Imam Abdulrahman bin Faisal University, Dammam, SA.
Background: Artificial intelligence (AI) is a revolutionary upcoming tool yet to be fully integrated into several healthcare sectors, including medical imaging. AI can transform how medical imaging is conducted and interpreted, especially in cardio-oncology.
Objective: This study aims to systematically review the available literature on the use of AI in cardio-oncology imaging to predict cardiotoxicity and describe the possible improvement of different imaging modalities that can be achieved if AI is successfully deployed to routine practice.
Acute therapy-related toxicities in pediatric acute lymphoblastic leukemia.
Haematologica
March 2025
Pediatric Hematology and Oncology, Schneider Children's Medical Center of Israel, and the Faculty of Medical and Health Sciences, Aviv University.
Most children diagnosed with acute lymphoblastic leukemia (ALL) will achieve remission and be cured of their disease. However, this high cure rate comes at the cost of acute and chronic treatment-related toxicities. In fact, a similar number of children die from either ALL itself or the toxicities associated with its treatment.
View Article and Find Full Text PDFAutologous P63+ lung progenitor cell transplantation in idiopathic pulmonary fibrosis: a phase 1 clinical trial.
Elife
March 2025
Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Background: In idiopathic pulmonary fibrosis (IPF) patients, alveolar architectures are lost and gas transfer function would decline, which cannot be rescued by conventional anti-fibrotic therapy. P63+ lung basal progenitor cells are reported to have potential to repair damaged lung epithelium in animal models, which need further investigation in clinical trials.
Methods: We cloned and expanded P63+ progenitor cells from IPF patients to manufacture cell product REGEND001, which were further characterized by morphology and single-cell transcriptomic analysis.
New insights into therapeutic strategies, drugs, and targets for advancing cancer therapy-related cardiovascular toxicity.
Sci Bull (Beijing)
February 2025
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China; State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!